Drugs / BR201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06126718 | Feb → Aug 2024 | psoriasis | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126718 ↗ |
| Route | Subcutaneous | “BR201 administered by subcutaneous injection” NCT06126718 ↗ |